What question did this study set out to answer?

This research investigates kidney impairment risk factors in patients with polycythemia vera and evaluates mouse models' similarities to human disease.

December 8, 2025BloodOpen Access

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

View Full Paper

Ask AI

Bookmark

Authors

MKMałgorzata Kasztan RPRafał Pawliński JHJ.E. Hamer-Maansson

Discussion

Member takes

Overview

Post hoc analysis shows rapid eGFR decline in polycythemia vera patients is linked to myelofibrosis and thromboembolism.

Key Points

This research investigates kidney impairment risk factors in patients with polycythemia vera and evaluates mouse models' similarities to human disease.
Analyzed real-world data from the Prospective Observational Study of patients with Polycythemia Vera (REVEAL).
Assessed serum creatinine and JAK2V617F status in patients over multiple years.
Evaluated kidney function in JAK2V617F-driven mouse models after IFNα treatment.
20.1% of patients had abnormal glomerular filtration rate (eGFR).
Rapid eGFR decline was associated with a higher rate of myelofibrosis progression.
Mouse models showed significant kidney impairment correlated with JAK2V617F mutation and histological changes.

Cite This Study

Kasztan et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd80 https://doi.org/10.1182/blood-2025-605

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

View Full Paper

Ask AI

Bookmark

Authors

MKMałgorzata Kasztan RPRafał Pawliński JHJ.E. Hamer-Maansson

Discussion

Member takes

Overview

Post hoc analysis shows rapid eGFR decline in polycythemia vera patients is linked to myelofibrosis and thromboembolism.

Key Points

This research investigates kidney impairment risk factors in patients with polycythemia vera and evaluates mouse models' similarities to human disease.
Analyzed real-world data from the Prospective Observational Study of patients with Polycythemia Vera (REVEAL).
Assessed serum creatinine and JAK2V617F status in patients over multiple years.
Evaluated kidney function in JAK2V617F-driven mouse models after IFNα treatment.
20.1% of patients had abnormal glomerular filtration rate (eGFR).
Rapid eGFR decline was associated with a higher rate of myelofibrosis progression.
Mouse models showed significant kidney impairment correlated with JAK2V617F mutation and histological changes.

Cite This Study

Kasztan et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd80 https://doi.org/10.1182/blood-2025-605

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark